Systemic treatments for cutaneous T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial looks at the results of different systemic (whole-body) treatments for cutaneous T-cell lymphoma (CTCL), a rare type of lymphoma that affects the skin. It aims to understand how well these therapies work and help guide future treatment choices.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of CTCL (a lymphoma that starts in the skin).
- You must be at least 18 years old.
- You must have started a systemic treatment (like a pill or infusion) that lasted at least 3 months, between January 2016 and December 2023.
- Your complete medical records must be available to the research team.
- You must sign a form saying you understand and agree to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing new treatment plans based on the genetic type of your cutaneous T-cell lymphoma (CTCL). It's for people whose CTCL did not respond well to standard skin treatments.
This trial is testing a cream called tofacitinib (a type of medicine that helps calm the immune system) for people with early-stage cutaneous T-cell lymphoma (CTCL). The goal is to see if it helps shrink or control the skin lesions safely.
This trial tests a medication called Ropeginterferon (a type of immune-supporting protein given as a shot) for people with different stages of cutaneous T-cell lymphoma. It may be an option if prior skin treatments haven't worked well enough.
This study looks at a new blood test that might help doctors diagnose Sézary syndrome (a rare type of skin lymphoma) and see how well treatment is working. It also checks for leftover disease after treatment.
This study collects blood, urine, and possibly small tissue samples to learn more about cutaneous T-cell lymphoma (CTCL) and either eczema or atopic dermatitis. It may help researchers better understand these skin conditions and improve future treatments.
This study tests a cream called benvitimod to see if it helps treat a type of skin lymphoma (mycosis fungoides). It may help control skin symptoms with less harsh side effects than other treatments.
Hear when a new Cutaneous T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.